Anebulo Pharmaceuticals (ANEB) announced the first subjects dosed in its Phase 1 single ascending dose study of intravenous selonabant in healthy young adults. The study is supported by a collaborative grant from the National Institute on Drug Abuse.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANEB: